CYCC — Clinical Trial Completion for Fadraciclib (CYC065) in Advanced Solid Tumors and Lymphoma
Jun 30, 2025, 4:00:00 AM UTC
Summary
Cyclacel Pharmaceuticals is conducting a Phase 1/2 clinical trial of Fadraciclib (CYC065), a CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma who have exhausted standard therapies. The trial, enrolling 330 participants across multiple cancer subtypes, is expected to complete on June 30, 2025. Fadraciclib is being evaluated for its potential to target cancers with specific molecular alterations, including MCL1, MYC, or CCNE amplification. The outcome may inform future development and regulatory strategy for this investigational oncology product.
Company
CYCLACEL PHARMACEUTICALS INC (CYCC)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.cyclacel.comSimilar Events
CYC140 Phase 1/2 Trial Completion Expected
Cyclacel Pharmaceuticals is conducting a Phase 1/2 clinical trial of CYC140, a PLK1 inhibitor, in patients with advanced solid tumors and lymphoma who have exhausted standard therapies. The study, enrolling approximately 330 participants, is expected to complete by November 1, 2025. CYC140 is an investigational oncology agent targeting multiple cancer types, including bladder, breast, lung, liver, colorectal, and various lymphomas. The trial's outcome may inform future development and regulatory strategies for CYC140.
trial completionCFT7455 Phase 1/2 Trial Completion in NHL and MM
C4 Therapeutics is expected to complete its Phase 1/2 clinical trial of CFT7455 (cemsidomide) in relapsed/refractory Non-Hodgkin's Lymphoma and Multiple Myeloma on December 7, 2025. The study evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral CFT7455, both as monotherapy and in combination with dexamethasone for MM. CFT7455 is a novel cereblon E3 ligase modulator (CELMoD) targeting hematologic malignancies.
trial completionCompletion of Phase 1/2a Clinical Trial for Narazaciclib Plus Letrozole in Endometrial Cancer
Traws Pharma is conducting a Phase 1/2a open-label, multicenter clinical trial evaluating the safety, tolerability, and efficacy of narazaciclib (ON 123300) in combination with letrozole for patients with recurrent metastatic low-grade endometrioid endometrial cancer and other gynecologic malignancies. The study, which began in March 2023, is expected to complete by February 1, 2026. Narazaciclib is an investigational oral CDK inhibitor, and letrozole is an aromatase inhibitor used in hormone-sensitive cancers.
trial completionExpected Completion of CGT4859 Phase 1/2 Trial in Cholangiocarcinoma and Solid Tumors
Cogent Biosciences is conducting a Phase 1/2 open-label trial of CGT4859, an FGFR2/3 inhibitor, in adults with intrahepatic cholangiocarcinoma and other advanced solid tumors harboring FGFR2 or FGFR3 alterations. The study, which began in January 2025, is expected to complete on June 1, 2027. The trial aims to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity in approximately 110 participants. CGT4859 is an investigational targeted therapy designed to inhibit FGFR2/3, which are implicated in certain cancers.
trial completion